| Upper Valley Family Medicine Pllc | |
|
711 Rigby Lake Dr Ste 115 Rigby ID 83442-5230 | |
| (208) 745-5021 | |
| (208) 745-5026 |
| Full Name | Upper Valley Family Medicine Pllc |
|---|---|
| Speciality | Family Medicine |
| Location | 711 Rigby Lake Dr Ste 115, Rigby, Idaho |
| Authorized Official Name and Position | Darin T Berrett (OFFICE MANAGER) |
| Authorized Official Contact | 2087455021 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Upper Valley Family Medicine Pllc 711 Rigby Lake Dr Ste 115 Rigby ID 83442-5230 Ph: (208) 745-5021 | Upper Valley Family Medicine Pllc 711 Rigby Lake Dr Ste 115 Rigby ID 83442-5230 Ph: (208) 745-5021 |
| NPI Number | 1073697884 |
|---|---|
| Provider Enumeration Date | 10/25/2006 |
| Last Update Date | 07/21/2022 |
| Medicare PECOS PAC ID | 9133195548 |
|---|---|
| Medicare Enrollment ID | O20040908000127 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073697884 | NPI | - | NPPES |
| 8067451700 | Medicaid | ID | |
| 806913600 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | William D Adams |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1467403733 PECOS PAC ID: 6507855418 Enrollment ID: I20040506001660 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
| Provider Name | Richard T Harper |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1477599538 PECOS PAC ID: 4981503760 Enrollment ID: I20041220000405 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
| Provider Name | Tiffany J Spaulding |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1679704753 PECOS PAC ID: 3274718036 Enrollment ID: I20110921000209 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
| Provider Name | Spencer G Stanger |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780194696 PECOS PAC ID: 4486913274 Enrollment ID: I20180124002909 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
| Provider Name | Justin Shippen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1871941724 PECOS PAC ID: 5698068427 Enrollment ID: I20190924000013 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
| Provider Name | Analee S Fish |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407405111 PECOS PAC ID: 0143657841 Enrollment ID: I20200302001391 |
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
News Archive
Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.
A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.
Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.
With the potential for targeted therapy, and therefore reduced side effects, nanomedicine holds the promise of significantly improving quality of life parameters.
Researchers at Montefiore Medical Center are leading a nationwide clinical trial to determine whether a new genetic test can be used to personalize treatment for early-stage breast cancer.
› Verified 4 days ago
Upper Valley Family Medicine Rhc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 530 Rigby Lake Dr, Rigby, ID 83442 Phone: 208-745-5021 Fax: 208-745-5026 | |
Zion Healing Center Rigby Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 205 Stockham Blvd Ste C-2, Rigby, ID 83442 Phone: 208-417-4899 | |
Renew 4 Life, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 240 S 5th W Ste E, Rigby, ID 83442 Phone: 208-745-0467 Fax: 208-745-0409 | |
Rigby Medical Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 477 Pleasant County Ln, Rigby, ID 83442 Phone: 208-359-6900 | |
Mountain View Hospital Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 167 E 1st S, Rigby, ID 83442 Phone: 208-745-8747 | |
Kurt E Kracaw Md Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 426 Farnsworth Way Ste 1, Rigby, ID 83442 Phone: 208-745-9411 Fax: 208-745-9910 |